HUMC 1612: Optune NovoTTF-200A System

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to determine if the Optune NovoTTF-200A device can be safely used in combination with chemotherapy in pediatric patients with recurrent high-grade glioma and ependemoma.

Clinical Trial Description

This phase I trial will utilize a standard 3+3 design to determine the safety and tolerability of the Optune NovoTTF-200A System in pediatric patients with recurrent high-grade glioma end ependemomas. Patients will receive treatment with the Optune NovoTTF-200A System along with Temozolomide and Bevacizumab and will consist of children with recurrent high-grade gliomas and Ependamomas. Patients enrolled will receive treatment with the Optune NovoTTF-200A with 200kHz for a minimum of 18 hours per day in 28 day cycles as monotherapy. Phase I safety evaluation will take place over the initial two cycles (56 days) of treatment. Following the completion of the safety evaluation period, patients will continue to receive treatment in 28 day cycles, which may be repeated continuously without therapy interruption for 12 cycles or until clinical criteria for discontinuation are met. Patients how appear to benefit from this treatment may be allowed to continue treatment beyond 12 cycles if approved by the study Principle Investigator. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03128047
Study type	Interventional
Source	Hackensack Meridian Health
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	April 6, 2017
Completion date	June 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05023551` - Study of DSP-0390 in Patients With Recurrent High-Grade Glioma	Early Phase 1
Terminated	`NCT01902771` - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors	Phase 1
Active, not recruiting	`NCT02655601` - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001	Phase 2
Terminated	`NCT03690869` - REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma	Phase 1/Phase 2
Completed	`NCT01466686` - Low Dose Radiation Therapy for Glioblastoma Multiforme	Phase 2
Recruiting	`NCT05212272` - MRI in High-Grade Glioma Patients Undergoing Chemoradiation
Recruiting	`NCT05925218` - Circulating Tumor DNA Collection From Patients With High Grade Gliomas
Active, not recruiting	`NCT04911621` - Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma	Phase 1/Phase 2
Not yet recruiting	`NCT06333899` - Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion	Early Phase 1
Recruiting	`NCT04734444` - SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue	N/A
Completed	`NCT03775369` - Glioma and Exercising	N/A
Completed	`NCT02022644` - Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma	Phase 1
Completed	`NCT00780819` - Borderzone Sampling	N/A
Recruiting	`NCT06072586` - Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) Participants With EGFR Alterations or Fusions	Early Phase 1
Completed	`NCT01390948` - A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma	Phase 2
Recruiting	`NCT03952598` - Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy	N/A
Recruiting	`NCT05630664` - Liquid Biopsy in High-grade Gliomas and Meningiomas
Recruiting	`NCT05298995` - GD2-CAR T Cells for Pediatric Brain Tumours	Phase 1
Completed	`NCT01222754` - Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas	Phase 1
Recruiting	`NCT05278208` - Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors	Phase 1/Phase 2